Search This Blog

Wednesday, August 5, 2026

Arcus ends Phase 3 PACIFIC-8 domvanalimab trial as partner Gilead relinquishes three board seats

 

Arcus Biosciences ends Phase 3 PACIFIC-8 domvanalimab trial as partner Gilead relinquishes three board seats

  • Changes announced in Arcus Biosciences’ second-quarter 2026 update as it streamlines collaboration with Gilead.
  • Arcus Biosciences reported Q2 2026 revenue of $41 million and a net loss of $91 million.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)